Third-generation oral contraceptives: future implications of current use

References

• Practice Committee of the American Society for Reproductive Medicine. Hormonal contraception: recent advances and controversies. Fertil. Steril.86(5 Suppl.), S229–S235 (2006).
   Google Scholar
• Cerel-Suhl SL, Yeager BF. Update on oral contraceptive pills. Am. Fam. Physician60(7), 2073–2084 (1999).
   PubMed Web of Science ®Google Scholar
• Poindexter A. The emerging use of the 20-microg oral contraceptive. Fertil. Steril.75(3), 457–465 (2001).
   PubMed Web of Science ®Google Scholar
• Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception60(6), 321–329 (1999).
   PubMed Web of Science ®Google Scholar
• Hammond GL, Rabe T, Wagner JD. Preclinical profiles of progestins used in formulations of oral contraceptives and hormone replacement therapy. Am. J. Obstet. Gynecol.185(2 Suppl.), S24–S31 (2001).
   Google Scholar
• Maitra N, Kulier R, Bloemenkamp KW, Helmerhorst FM, Gulmezoglu AM. Progestogens in combined oral contraceptives for contraception. Cochrane Database Syst. Rev.3, CD004861 (2004).
   PubMedGoogle Scholar
• Moreau C, Trussell J, Gilbert F, Bajos N, Bouyer J. Oral contraceptive tolerance: does the type of pill matter? Obstet. Gynecol.109(6), 1277–1285 (2007).
   PubMed Web of Science ®Google Scholar
• Jordan W. Pulmonary embolism. Lancet2, 1146–1147 (1961).
   Google Scholar
• World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet346(8990), 1582–1588 (1995).
   Google Scholar
• Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ316(7136), 984–987 (1998).
   PubMedGoogle Scholar
• Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet346(8990), 1589–1593 (1995).
   PubMed Web of Science ®Google Scholar
• Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women. BMJ312(7023), 83–88 (1996).
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Rosing J, Bloemenkamp KW et al. Oral contraceptives and the risk of venous thrombosis. N. Engl. J. Med.344(20), 1527–1535 (2001).
   PubMed Web of Science ®Google Scholar
• Jick SS, Vasilakis C, Jick H. Pregnancies and terminations after 1995 warning about third-generation oral contraceptives. Lancet351(9113), 1404–1405 (1998).
   Google Scholar
• O’Brien PA. The third generation oral contraceptive controversy. The evidence shows they are less safe than second generation pills. BMJ319(7213), 795–796 (1999).
   PubMed Web of Science ®Google Scholar
• Medicines Commission. Combined oral contraceptives containing desogestrel or gestodene and the risk of venous thromboembolism. Curr. Probl. Pharmacovigilance25, 12 (1999).
   Google Scholar
• Middeldorp S, Meijers JC, van den Ende AE et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb. Haemost.84(1), 4–8 (2000).
   PubMed Web of Science ®Google Scholar
• Rosing J, Middeldorp S, Curvers J et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet354(9195), 2036–2040 (1999).
   PubMed Web of Science ®Google Scholar
• Farley TM, Meirik O, Collins J. Cardiovascular disease and combined oral contraceptives: reviewing the evidence and balancing the risks. Hum. Reprod. Update5(6), 721–735 (1999).
   PubMed Web of Science ®Google Scholar
• World Health Organization Collaborative Study of Cardiovascular Disease and us Steroid Hormone Contraception. Cardiovascular disease and use of oral injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case control study. Contraception57, 315–324 (1998).
   Google Scholar
• Boyce J, Fawcett J, Noall E. Coronary thrombosis and Conovid. Lancet1, 111 (1963).
   PubMed Web of Science ®Google Scholar
• Tanis BC, van den Bosch MA, Kemmeren JM et al. Oral contraceptives and the risk of myocardial infarction. N. Engl. J. Med.345(25), 1787–1793 (2001).
   PubMed Web of Science ®Google Scholar
• Dunn N, Thorogood M, Faragher B et al. Oral contraceptives and myocardial infarction: results of the MICA case–control study. BMJ318(7198), 1579–1583 (1999).
   PubMed Web of Science ®Google Scholar
• Khader YS, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis. Contraception68(1), 11–17 (2003).
   PubMed Web of Science ®Google Scholar
• Baillargeon JP, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab.90(7), 3863–3870 (2005).
   PubMed Web of Science ®Google Scholar
• Kemmeren JM, Tanis BC, van den Bosch MA et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke33(5), 1202–1208 (2002).
   PubMed Web of Science ®Google Scholar
• Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet347(9017), 1713–1727 (1996).
   Google Scholar
• Newcomb PA, Longnecker MP, Storer BE et al. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control7(5), 525–532 (1996).
   Google Scholar
• Brinton LA, Gammon MD, Malone KE et al. Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women. Contraception55(4), 197–203 (1997).
   PubMed Web of Science ®Google Scholar
• McCredie MR, Dite GS, Giles GG, Hopper JL. Breast cancer in Australian women under the age of 40. Cancer Causes Control9(2), 189–198 (1998).
   Google Scholar
• Ursin G, Ross RK, Sullivan-Halley J et al. Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res. Treat.50(2), 175–184 (1998).
   PubMed Web of Science ®Google Scholar
• Marchbanks PA, McDonald JA, Wilson HG et al. Oral contraceptives and the risk of breast cancer. N. Engl. J. Med.346(26), 2025–2032 (2002).
   PubMed Web of Science ®Google Scholar
• Kumle M, Weiderpass E, Braaten T et al. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women’s Lifestyle and Health Cohort Study. Cancer Epidemiol. Biomarkers Prev.11(11), 1375–1381 (2002).
   PubMed Web of Science ®Google Scholar
• Magnusson C, Baron JA, Correia N et al. Breast-cancer risk following long-term oestrogen- and oestrogen–progestin-replacement therapy. Int. J. Cancer81(3), 339–344 (1999).
   PubMed Web of Science ®Google Scholar
• Grabrick DM, Hartmann LC, Cerhan JR et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA284(14), 1791–1798 (2000).
   PubMed Web of Science ®Google Scholar
• Narod SA, Dube MP, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst.94(23), 1773–1779 (2002).
   PubMed Web of Science ®Google Scholar
• Schlesselman J, Collins J. The influence of steroids on gynecoogic cancers. In: Estrogens and Progestogens in Clinical Practice. Fraser IS (Ed.). Churchill–Livingstone, London, UK (1999).
   Google Scholar
• The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institue of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oral contraceptive use. N. Engl. J. Med.316, 650–655 (1987).
   Google Scholar
• Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J. Natl Cancer Inst.94(1), 32–38 (2002).
   PubMed Web of Science ®Google Scholar
• Modan B, Hartge P, Hirsh-Yechezkel G et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N. Engl. J. Med.345(4), 235–240 (2001).
   PubMed Web of Science ®Google Scholar
• Weiderpass E, Adami HO, Baron JA et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control10(4), 277–284 (1999).
   PubMed Web of Science ®Google Scholar
• Hormonal contraception: recent advances and controversies. Fertil. Steril.86(5 Suppl. 1), S229–S235 (2006).
   Google Scholar
• Polatti F, Perotti F, Filippa N, Gallina D, Nappi RE. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception51(4), 221–224 (1995).
   PubMed Web of Science ®Google Scholar
• Elgan C, Dykes AK, Samsioe G. Bone mineral density changes in young women: a two year study. Gynecol. Endocrinol.19(4), 169–177 (2004).
   PubMed Web of Science ®Google Scholar
• Prior JC, Kirkland SA, Joseph L et al. Oral contraceptive use and bone mineral density in premenopausal women: cross-sectional, population-based data from the Canadian Multicentre Osteoporosis Study. CMAJ165(8), 1023–1029 (2001).
   Web of Science ®Google Scholar
• Cooper C, Hannaford P, Croft P, Kay CR. Oral contraceptive pill use and fractures in women: a prospective study. Bone14(1), 41–45 (1993).
   PubMed Web of Science ®Google Scholar
• Hartard M, Kleinmond C, Kirchbichler A et al. Age at first oral contraceptive use as a major determinant of vertebral bone mass in female endurance athletes. Bone35(4), 836–841 (2004).
   Google Scholar
• Hartard M, Kleinmond C, Wiseman M et al. Detrimental effect of oral contraceptives on parameters of bone mass and geometry in a cohort of 248 young women. Bone40(2), 444–450 (2007).
   PubMed Web of Science ®Google Scholar
• d’Arcangues C. WHO statement on hormonal contraception and bone health. Contraception73(5), 443–444 (2006).
   PubMed Web of Science ®Google Scholar
• World Health Organization Reproductive Health and Research. Medical Eligibility Criteria for Contraceptive Use. WHO, Geneva, Switzerland (2004).
   Google Scholar
• O’Malley BW. Coregulators: from whence came these “master genes”. Mol. Endocrinol.21(5), 1009–1013 (2007).
   PubMed Web of Science ®Google Scholar
• Georgiakaki M, Chabbert-Buffet N, Dasen B et al. Ligand-controlled interaction of histone acetyltransferase binding to ORC-1 (HBO1) with the N-terminal transactivating domain of progesterone receptor induces steroid receptor coactivator 1-dependent coactivation of transcription. Mol. Endocrinol.20(9), 2122–2140 (2006).
   PubMedGoogle Scholar
• Mulac-Jericevic B, Conneely OM. Reproductive tissue selective actions of progesterone receptors. Reproduction128(2), 139–146 (2004).
   PubMed Web of Science ®Google Scholar
• Pascual-Le Tallec L, Lombes M. The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol. Endocrinol.19(9), 2211–2221 (2005).
   PubMedGoogle Scholar
• Duma D, Jewell CM, Cidlowski JA. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol.102(1–5), 11–21 (2006).
   PubMed Web of Science ®Google Scholar
• Zerr-Fouineau M, Chataigneau M, Blot C, Schini-Kerth VB. Progestins overcome inhibition of platelet aggregation by endothelial cells by down-regulating endothelial NO synthase via glucocorticoid receptors. FASEB J.21(1), 265–273 (2007).
   PubMed Web of Science ®Google Scholar
• Chataigneau T, Zerr M, Chataigneau M et al. Chronic treatment with progesterone but not medroxyprogesterone acetate restores the endothelial control of vascular tone in the mesenteric artery of ovariectomized rats. Menopause11(3), 255–263 (2004).
   PubMed Web of Science ®Google Scholar
• Finlay IG, Scott MG. Patterns of contraceptive pill taking in an inner city practice. Br. Med. J.293(6547), 601–602 (1986).
   PubMed Web of Science ®Google Scholar
• van Heusden AM, Fauser BC. Residual ovarian activity during oral steroid contraception. Hum. Reprod. Update8(4), 345–358 (2002).
   PubMed Web of Science ®Google Scholar
• Barbosa IC, Filho CI, Faggion D Jr, Baracat EC. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse). Contraception73(1), 30–33 (2006).
   PubMed Web of Science ®Google Scholar
• Sabatini R, Cagiano R. Comparison profiles of cycle control, side effects and sexual satisfaction of three hormonal contraceptives. Contraception74(3), 220–223 (2006).
   PubMed Web of Science ®Google Scholar
• Edelman A, Gallo MF, Nichols MD et al. Continuous versus cyclic use of combined oral contraceptives for contraception: systematic Cochrane review of randomized controlled trials. Hum. Reprod.21(3), 573–578 (2006).
   PubMed Web of Science ®Google Scholar
• Canonico M, Oger E, Plu-Bureau G et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation115(7), 840–845 (2007).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Plu-Bureau G, Menard J et al. Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J. Clin. Endocrinol. Metab.92(6), 2074–2079 (2007).
   PubMed Web of Science ®Google Scholar
• O’Connell K, Burkman RT. The transdermal contraceptive patch: an updated review of the literature. Clin. Obstet. Gynecol.50(4), 918–926 (2007).
   PubMed Web of Science ®Google Scholar
• Gompel A, Carpentier S, Frances C, Piette JC. Risk of venous thromboembolism and oral contraceptives. Lancet359(9314), 1348–1349 (2002).
   Google Scholar
• Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet358(9291), 1427–1429 (2001).
   PubMed Web of Science ®Google Scholar
• Seaman HE, de Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case–control study. Hum. Reprod.18(3), 522–526 (2003).
   PubMed Web of Science ®Google Scholar
• Spitzer WO. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: an epidemiological evaluation. J. Obstet. Gynaecol. Can.25(12), 1011–1018 (2003).
   Google Scholar
• Mastorakos G, Koliopoulos C, Deligeoroglou E, Diamanti-Kandarakis E, Creatsas G. Effects of two forms of combined oral contraceptives on carbohydrate metabolism in adolescents with polycystic ovary syndrome. Fertil. Steril.85(2), 420–427 (2006).
   PubMed Web of Science ®Google Scholar
• Bouchard P. Chlormadinone Acetate (CMA) in oral contraception. A new opportunity. Fertil. Contracept.10(Suppl. 1), 7–11 (2005).
   Google Scholar
• Conard J, Plu-Bureau G, Bahi N et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception70(6), 437–441 (2004).
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception62(1), 29–38 (2000).
   PubMed Web of Science ®Google Scholar
• Fenton C, Wellington K, Moen MD, Robinson DM. Drospirenone/ ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in Contraception premenstrual dysphoric disorder and moderate acne vulgaris. Drugs67(12), 1749–1765 (2007).
   PubMed Web of Science ®Google Scholar
• Seeger JD, Loughlin J, Eng PM et al. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet. Gynecol.110(3), 587–593 (2007).
   PubMed Web of Science ®Google Scholar
• Bazin B, Thevenot R, Bursaux C, Paris J. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br. J. Obstet. Gynaecol.94(12), 1199–1204 (1987).
   PubMedGoogle Scholar
• Jamin C, Batallan A, Madelenat P. Antigonadotropic effects of a 19-nor-progesterone derivative: the example of nomegestrol acetate. Gynecol. Obstet. Fertil.31, 70–83 (2003).
   Google Scholar
• Couzinet B, Young J, Kujas M et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J. Clin. Endocrinol. Metab.84(11), 4191–4196 (1999).
   PubMed Web of Science ®Google Scholar
• Korver T, Klipping C, Heger-Mahn D et al. Maintenance of ovulation inhibition with the 75-microg desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake. Contraception71(1), 8–13 (2005).
   PubMed Web of Science ®Google Scholar
• Meirik O, Farley TM, Sivin I. Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet. Gynecol.,97(4), 539–547 (2001).
   PubMed Web of Science ®Google Scholar
• Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception65(1), 29–37 (2002).
   PubMed Web of Science ®Google Scholar
• Kovacs G. Progestogen-only pills and bleeding disturbances. Hum. Reprod.11(Suppl. 2), 20–23 (1996).
   PubMed Web of Science ®Google Scholar
• Verbost PM, Hanssen RG, Korver GH, Mulders TM. ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens. Semin. Reprod. Med.23(1), 101–111 (2005).
   PubMed Web of Science ®Google Scholar
• Croxatto HB, Salvatierra AM, Fuentealba B, Massai R. Contraceptive potential of a mifepristone-nomegestrol acetate sequential regimen in women. Hum. Reprod.13(12), 3297–3302 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng L, Zhu H, Wang A et al. Once a month administration of mifepristone improves bleeding patterns in women using subdermal contraceptive implants releasing levonorgestrel. Hum. Reprod.15(9), 1969–1972 (2000).
   PubMed Web of Science ®Google Scholar
• Weisberg E, Hickey M, Palmer D et al. A pilot study to assess the effect of three short-term treatments on frequent and/or prolonged bleeding compared to placebo in women using Implanon. Hum. Reprod.21(1), 295–302 (2006).
   PubMed Web of Science ®Google Scholar
• Spitz IM, Van Look PF, Coelingh Bennink HJ. The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids65(10–11), 817–823 (2000).
   PubMed Web of Science ®Google Scholar
• Ledger WL, Sweeting VM, Hillier H, Baird DT. Inhibition of ovulation by low-dose mifepristone (RU 486). Hum. Reprod.7(7), 945–950 (1992).
   PubMed Web of Science ®Google Scholar
• Brown A, Cheng L, Lin S, Baird DT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J. Clin. Endocrinol. Metab.87(1), 63–70 (2002).
   PubMed Web of Science ®Google Scholar
• Pei K, Xiao B, Jing X et al. Weekly contraception with mifepristone. Contraception75(1), 40–44 (2007).
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard P. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab.92(9), 3582–3589 (2007).
   PubMed Web of Science ®Google Scholar
• Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet. Gynecol.103(6), 1331–1336 (2004).
   PubMed Web of Science ®Google Scholar
• Lakha F, Ho PC, Van der Spuy ZM et al. A novel estrogen-free oral contraceptive pill for women: multicentre, double-blind, randomized controlled trial of mifepristone and progestogen-only pill (levonorgestrel). Hum. Reprod.22(9), 2428–2436 (2007).
   PubMed Web of Science ®Google Scholar
• Williams AR, Critchley HO, Osei J et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum. Reprod.22(6), 1696–1704 (2007).
   PubMed Web of Science ®Google Scholar
• Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum. Reprod. Update13(6), 567–580 (2007).
   PubMed Web of Science ®Google Scholar
• Heikinheimo O, Vani S, Carpen O et al. Intrauterine release of progesterone antagonist ZK230211 is feasible and results in novel endometrial effects: a pilot study. Hum. Reprod.22(9), 2515–2522 (2007).
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R. Vaginal delivery of contraceptives. Expert Opin. Drug Delivery,2(4), 729–736 (2005).
   PubMedGoogle Scholar